- Conditions
- Acute Myeloid Leukemia, Myelodysplasia
- Interventions
- MGTA-117
- Biological
- Lead sponsor
- Magenta Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 8
- States / cities
- Duarte, California • Denver, Colorado • Tampa, Florida + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 217–240
of 2,062
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Anemia
- Interventions
- methoxy polyethylene glycol-epoetin beta [Mircera]
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 137 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2005
- U.S. locations
- 6
- States / cities
- Los Angeles, California • San Jose, California • Boston, Massachusetts + 3 more
- Conditions
- Multiple Myeloma, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Non Hodgkin Lymphoma, Acute Lymphocytic Leukemia, Hodgkin Lymphoma, Hodgkin Disease, Myelofibrosis, Myelodysplastic Syndromes, Myeloproliferative Neoplasm, Sickle Cell Disease, Mantle Cell Lymphoma
- Interventions
- Pre-biotic foods/drinks
- Other
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Pyruvate Kinase Deficiency, Anemia, Hemolytic
- Interventions
- AG-348
- Drug
- Lead sponsor
- Agios Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 4
- States / cities
- Oakland, California • Atlanta, Georgia • Boston, Massachusetts + 1 more
- Conditions
- Sickle Cell Crisis
- Interventions
- Virtual Reality Goggles
- Other
- Lead sponsor
- University of Mississippi Medical Center
- Other
- Eligibility
- 6 Years to 21 Years
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Jackson, Mississippi
- Conditions
- Myelofibrosis, Myelofibrosis; Anemia
- Interventions
- Nelfinavir
- Drug
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Orange, California
- Conditions
- Non-Transfusion Dependent Beta-Thalassemia (NTDT)
- Interventions
- REGN7999, Placebo
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Sickle Cell Disease, Executive Dysfunction, Cognitive Impairment, Attention Deficit/Hyperactivity Disorder (ADHD)
- Interventions
- Extended-Release Methylphenidate
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 8 Years to 17 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Thrombotic Microangiopathy, Thrombotic Thrombocytopenic Purpura
- Interventions
- ARC 1779 Placebo, ARC1779 Injection
- Drug
- Lead sponsor
- Archemix Corp.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 7
- States / cities
- Chicago, Illinois • Indianapolis, Indiana • St Louis, Missouri + 4 more
- Conditions
- Sickle Cell Disease
- Interventions
- Liver transient elastography (Fibroscan), Ferriscan, Liver biopsy in iron overloaded subjects.
- Other · Procedure
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 10 Years to 65 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Sickle Cell Disease
- Interventions
- Peer Community Health Worker, Mobile Health
- Other
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 17 Years and older
- Enrollment
- 405 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2024
- U.S. locations
- 5
- States / cities
- Hartford, Connecticut • New Hyde Park, New York • Cincinnati, Ohio + 1 more
- Conditions
- Leiomyomas
- Interventions
- Ulipristal Acetate, Iron
- Drug
- Lead sponsor
- Watson Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 47
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 41 more
- Conditions
- Diamond Blackfan Anemia
- Interventions
- Mobilization Regimen
- Drug
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 3 Years to 30 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- New Hyde Park, New York
- Conditions
- Atypical Hemolytic Uremic Syndrome
- Interventions
- Eculizumab
- Other
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 8
- States / cities
- Washington D.C., District of Columbia • Atlanta, Georgia • Chicago, Illinois + 5 more
- Conditions
- Hairy Cell Leukemia (HCL), Chronic Lymphocytic Leukemia (CLL), Non-Hodgkins Lymphoma (NHL), Cutaneous T Cell Lymphoma (CTCL), Adult T Cell Lymphoma (ATL)
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 1,263 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2010
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Sickle Cell Disease Vaso-occlusive Crisis
- Interventions
- CSL889, Placebo
- Biological · Drug
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 20
- States / cities
- Oakland, California • Orange, California • Washington D.C., District of Columbia + 15 more
- Conditions
- Acute Myeloid Leukemia in Remission, Adult Acute Lymphoblastic Leukemia in Complete Remission, Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission, Chronic Myelomonocytic Leukemia in Remission, Graft Versus Host Disease, Hodgkin Lymphoma, Minimal Residual Disease, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma, Plasma Cell Myeloma, Severe Aplastic Anemia, Waldenstrom Macroglobulinemia
- Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Melphalan Hydrochloride, Mycophenolate Mofetil, Sirolimus, Total-Body Irradiation
- Procedure · Drug · Other + 1 more
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Anemia, Surgery
- Interventions
- Monoferric
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Sickle Cell Disease, Sickle Cell Anemia, Sickle Cell Disorders, Hemoglobin S Disease, Sickling Disorder Due to Hemoglobin S
- Interventions
- HQK-1001
- Drug
- Lead sponsor
- HemaQuest Pharmaceuticals Inc.
- Industry
- Eligibility
- 12 Years to 60 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2011
- U.S. locations
- 9
- States / cities
- Oakland, California • Miami, Florida • Augusta, Georgia + 6 more
- Conditions
- End Stage Renal Disease
- Interventions
- Erythropoietin, Pentoxifylline
- Drug
- Lead sponsor
- Fresenius Medical Care North America
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 10
- States / cities
- Chicago, Illinois • Kalamazoo, Michigan • Brookhaven, Mississippi + 7 more
- Conditions
- Thrombotic Thrombocytopenic Purpura, Congenital Thrombotic Thrombocytopenic Purpura, Familial Thrombotic Thrombocytopenic Purpura, Thrombotic Thrombocytopenic Purpura, Congenital, Upshaw-Schulman Syndrome
- Interventions
- Observation
- Other
- Lead sponsor
- Insel Gruppe AG, University Hospital Bern
- Other
- Eligibility
- Not listed
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2030
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Sickle Cell Disease
- Interventions
- BEAM-101
- Biological
- Lead sponsor
- Beam Therapeutics Inc.
- Industry
- Eligibility
- 12 Years to 35 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Jacksonville, Florida + 14 more
- Conditions
- Sickle Cell Disease
- Interventions
- Hydromorphone (Standardized, weight-based dosing), Morphine Sulfate (Standardized, weight-based dosing), Hydromorphone (Patient Specific dosing), Morphine Sulfate (Patient Specific dosing)
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 2
- States / cities
- New York, New York • Cincinnati, Ohio
- Conditions
- Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Interventions
- arsenic trioxide
- Drug
- Lead sponsor
- CTI BioPharma
- Industry
- Eligibility
- 18 Years to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2005
- U.S. locations
- 8
- States / cities
- Tucson, Arizona • La Jolla, California • Los Angeles, California + 4 more